NCT01565252

Brief Summary

Study Rationale: As epidemiological research has shown negative effects of high egg consumption on increased all-cause mortality and diabetes and on diabetes outcomes, and egg modification may modulate their effects on diseases risks, it is important to test the effect of eggs with different composition on markers associated with dyslipidemia, dysglycemia and inflammation. The aim of this study is to assess the effect of n-3PUFA (Omega 3) fortified egg compared to omega-6 Israeli regular egg on metabolic, inflammation and other physiologic parameters.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
20

participants targeted

Target at P25-P50 for not_applicable healthy-volunteers

Timeline
Completed

Started Apr 2014

Typical duration for not_applicable healthy-volunteers

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 9, 2012

Completed
19 days until next milestone

First Posted

Study publicly available on registry

March 28, 2012

Completed
2 years until next milestone

Study Start

First participant enrolled

April 1, 2014

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2015

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2015

Completed
Last Updated

November 25, 2013

Status Verified

February 1, 2013

Enrollment Period

1.1 years

First QC Date

March 9, 2012

Last Update Submit

November 21, 2013

Conditions

Keywords

Egg,Omega 3, Omega 6

Outcome Measures

Primary Outcomes (1)

  • Glycemic levels

    Pre- and Post-prandial (before meal and 30 and 60 minutes after meal) blood glucose test

    before meal and 30 and 60 minutes after meal

Secondary Outcomes (3)

  • Fatty Acid Composition

    Study Days:1,21,43 and 63

  • C-Reactive protein

    Study Days:1, 21, 43 and 63

  • MDA(Malondialdehyde)

    Study days: 1,21,43 and 63

Study Arms (2)

Stage 1

NO INTERVENTION

Dietary regimens: Stage1 - all participants (N=20) in first stage will receive two regular (high n-6 PUFA) hard-boiled eggs/day at breakfast for a three weeks period for each participant.

Stage 2

EXPERIMENTAL

Stage 2 will be conduct after 3 weeks for wash-out with no eggs. All participants(N=20) in second stage will receive two high n-3 PUFA hard-boiled eggs/day at breakfast for a three weeks period for each participant.

Dietary Supplement: eggs enriched Omega-3

Interventions

eggs enriched Omega-3DIETARY_SUPPLEMENT

In second stage participants will receive two Omega-3 enriched hard-boiled eggs/day at breakfast for a three weeks period for each participant.

Stage 2

Eligibility Criteria

Age18 Years - 45 Years
Sexmale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Healthy men volunteers (age 18-45 years)
  • BMI 23-28

You may not qualify if:

  • Use of lipid-modifying medications or nutritional supplements
  • Known malignancy
  • Allergy to eggs or other materials use in the experiment
  • Substance abuse (including alcohol

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Rabin Medical Center, Campus Beilinson

Petah Tikva, Petach Tikva, 49100, Israel

Location

Study Officials

  • Pierre Singer, Professor,MD

    ICU dep't, Institute for Nutrition Research, Rabin MC

    PRINCIPAL INVESTIGATOR
  • Niva Shapiro, Ph.D.,R.D.

    Institute for Nutrition Research, Rabin MC

    STUDY CHAIR
  • Milana Grinev, Study Coordinator

    ICU dep't, Institute for Nutrition Research, Rabin MC

    STUDY DIRECTOR

Central Study Contacts

Pierre Singer, MD,Professor

CONTACT

Milana Grinev, Study Coordinator

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
SUPPORTIVE CARE
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor, MD

Study Record Dates

First Submitted

March 9, 2012

First Posted

March 28, 2012

Study Start

April 1, 2014

Primary Completion

May 1, 2015

Study Completion

August 1, 2015

Last Updated

November 25, 2013

Record last verified: 2013-02

Locations